Preclinical development of the nicotinamide phosphoribosyl transferase inhibitor prodrug GMX1777-Reference-Cited by-同舟云学术

Preclinical development of the nicotinamide phosphoribosyl transferase inhibitor prodrug GMX1777

Published:2009-06 Issue:5 Volume:20 Page:346-354
ISSN:0959-4973
Container-title:Anti-Cancer Drugs
language:en
Short-container-title:

Author:

Beauparlant Pierre,Bédard Dominique,Bernier Cynthia,Chan Helen,Gilbert Karine,Goulet Daniel,Gratton Michel-Olivier,Lavoie Manon,Roulston Anne,Turcotte Émilie,Watson Mark

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Cancer Research,Pharmacology (medical),Pharmacology,Oncology

Reference19 articles.

1. EB1627: a soluble prodrug of the potent anticancer cyanoguanidine CHS828;Binderup;Bioorg Med Chem Lett,2005

2. Novel cyanoguanidines with potent oral antitumor activity;Schou;Bioorg Med Chem Lett,1997

3. Anticancer agent CHS-828 inhibits cellular synthesis of NAD;Olesen;Biochem Biophys Res Commun,2008

4. Nicotinamide adenine dinucleotide metabolism as an attractive target for drug discovery;Khan;Expert Opin Ther Targets,2007

5. CHS 828, a novel pyridyl cyanoguanidine with potent antitumor activity in vitro and in vivo;Hjarnaa;Cancer Res,1999

Cited by 57 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Dual-targeted NAMPT inhibitors as a progressive strategy for cancer therapy;Bioorganic Chemistry;2024-08

2. Discovery of potent and novel dual NAMPT/BRD4 inhibitors for efficient treatment of hepatocellular carcinoma;European Journal of Medicinal Chemistry;2024-05

3. Discovery of potent NAMPT-Targeting PROTACs using FK866 as the warhead;Bioorganic & Medicinal Chemistry Letters;2023-08

4. The Biocatalysis in Cancer Therapy;ACS Catalysis;2023-05-25

5. Anticancer Activities of Novel Nicotinamide Phosphoribosyltransferase Inhibitors in Hematological Malignancies;Molecules;2023-02-16